This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ragheb, S. Articles by Lisak, R. Search for Related Content PubMed PubMed Citation Articles by Ragheb, S. Articles by Lisak, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Autoimmune Diseases Multiple Sclerosis Social Bookmarking                   What's this?

Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells

Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA

Sarah Abramczyk

Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA

Deena Lisak

Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA

Robert Lisak

Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA, Department of Immunology & Microbiology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA

Glatiramer acetate (GA) is an immunotherapeutic drug for multiple sclerosis (MS). Several mechanisms of action have been demonstrated which target and affect T-cells that are specific for myelin antigen epitopes. We measured the in vitro proliferation of GA-responsive T-cells from untreated MS patients and from normal healthy subjects; in addition, we determined the effect of prolonged GA therapy or interferon-b therapy on the in vitro proliferation of GA-responsive T-cells of MS patients. We found that GA induces the proliferation of T-cells isolated from individuals who have not been previously exposed to GA, and that long-term in vivo therapy of MS patients with GA abrogates the GA-induced proliferative response of T-cells. In GA-treated patients, there is no evidence of generalized immunosuppression; both tetanus toxoid and anti-CD3 induced proliferative responses remain unaffected. We propose that prolonged in vivo exposure to GA may result in the eventual induction of anergy or deletion of a population of GA-responsive cells that may also be T-cells that are pathogenic in MS. This mechanism of action, in addition to other mechanisms that have been demonstrated, suggests that GA has pleiotropic effects on the immune system in MS.

Key Words: multiple sclerosis • T-cells • glatiramer acetate • immune system • tolerance

Multiple Sclerosis, Vol. 7, No. 1, 43-47 (2001)
DOI: 10.1177/135245850100700108


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF]

				R.M. Valenzuela, K. Costello, M. Chen, A. Said, K.P. Johnson, and S. Dhib-Jalbut Clinical response to glatiramer acetate correlates with modulation of IFN-{gamma} and IL-4 expression in multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 754 - 762. [Abstract] [PDF]

				C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320. [Abstract] [PDF]